View Item 

Show simple item record

Similar clinical benefits from below‐target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial
dc.contributor.authorLam, Phillip H.
dc.contributor.authorDooley, Daniel J.
dc.contributor.authorFonarow, Gregg C.
dc.contributor.authorButler, Javed
dc.contributor.authorBhatt, Deepak L.
dc.contributor.authorFilippatos, Gerasimos S.
dc.contributor.authorDeedwania, Prakash
dc.contributor.authorForman, Daniel E.
dc.contributor.authorWhite, Michel
dc.contributor.authorFletcher, Ross D.
dc.contributor.authorArundel, Cherinne
dc.contributor.authorBlackman, Marc R.
dc.contributor.authorAdamopoulos, Chris
dc.contributor.authorKanonidis, Ioannis E.
dc.contributor.authorAban, Inmaculada B.
dc.contributor.authorPatel, Kanan
dc.contributor.authorAronow, Wilbert S.
dc.contributor.authorAllman, Richard M.
dc.contributor.authorAnker, Stefan D.
dc.contributor.authorPitt, Bertram
dc.contributor.authorAhmed, Ali
dc.date.accessioned2018-03-07T18:25:27Z
dc.date.available2019-04-01T15:01:10Zen
dc.date.issued2018-02
dc.identifier.citationLam, Phillip H.; Dooley, Daniel J.; Fonarow, Gregg C.; Butler, Javed; Bhatt, Deepak L.; Filippatos, Gerasimos S.; Deedwania, Prakash; Forman, Daniel E.; White, Michel; Fletcher, Ross D.; Arundel, Cherinne; Blackman, Marc R.; Adamopoulos, Chris; Kanonidis, Ioannis E.; Aban, Inmaculada B.; Patel, Kanan; Aronow, Wilbert S.; Allman, Richard M.; Anker, Stefan D.; Pitt, Bertram; Ahmed, Ali (2018). "Similar clinical benefits from below‐target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial." European Journal of Heart Failure 20(2): 359-369.
dc.identifier.issn1388-9842
dc.identifier.issn1879-0844
dc.identifier.urihttps://hdl.handle.net/2027.42/142515
dc.publisherJohn Wiley & Sons, Ltd
dc.subject.otherEnalapril
dc.subject.otherPlacebo
dc.subject.otherHeart failure
dc.subject.otherTarget dose
dc.subject.otherACE inhibitors
dc.titleSimilar clinical benefits from below‐target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142515/1/ejhf937.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142515/2/ejhf937_am.pdf
dc.identifier.doi10.1002/ejhf.937
dc.identifier.sourceEuropean Journal of Heart Failure
dc.identifier.citedreferenceMaggioni AP. Outcome improvement of patients with heart failure and reduced ejection fraction: has it ended in the new millennium? Eur J Heart Fail 2016; 18: 512 – 513.
dc.identifier.citedreferenceKoudstaal S, Pujades‐Rodriguez M, Denaxas S, Gho JMIH, Shah AD, Yu N, Patel RS, Gale CP, Hoes AW, Cleland JG, Asselbergs FW, Hemingway H. Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population‐based linked electronic health record cohort study in 2.1 million people. Eur J Heart Fail 2017; 19: 1119 – 1127.
dc.identifier.citedreferenceMaggioni AP, Orso F, Calabria S, Rossi E, Cinconze E, Baldasseroni S, Martini N; ARNO Observatory. The real‐world evidence of heart failure: findings from 41 413 patients of the ARNO database. Eur J Heart Fail 2016; 18: 402 – 410.
dc.identifier.citedreferenceYancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2016; 68: 1476 – 1488.
dc.identifier.citedreferenceVoors AA, Gori M, Liu LC, Claggett B, Zile MR, Pieske B, McMurray JJ, Packer M, Shi V, Lefkowitz MP, Solomon SD; PARAMOUNT Investigators. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2015; 17: 510 – 517.
dc.identifier.citedreferenceDamman K, Solomon SD, Pfeffer MA, Swedberg K, Yusuf S, Young JB, Rouleau JL, Granger CB, McMurray JJ. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM‐study programme. Eur J Heart Fail 2016; 18: 1508 – 1517.
dc.identifier.citedreferenceVardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, Teerlink JR, Desai AS, Lefkowitz M, Shi V, McMurray JJ, Solomon SD; Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM‐HF) Investigators. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial. Eur J Heart Fail 2016; 10: 1228 – 1234.
dc.identifier.citedreferenceBanach M, Bhatia V, Feller MA, Mujib M, Desai RV, Ahmed MI, Guichard JL, Aban I, Love TE, Aronow WS, White M, Deedwania P, Fonarow G, Ahmed A. Relation of baseline systolic blood pressure and long‐term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol 2011; 107: 1208 – 1214.
dc.identifier.citedreferenceDries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35: 681 – 689.
dc.identifier.citedreferenceKonstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole‐Wilson PA; HEAAL Investigators. Effects of high‐dose versus low‐dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double‐blind trial. Lancet 2009; 374: 1840 – 1848.
dc.identifier.citedreferenceThe NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998; 19: 481 – 489.
dc.identifier.citedreferencePacker M, Poole‐Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Rydén L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin‐converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100: 2312 – 2318.
dc.identifier.citedreferenceThe SOLVD Investigators. Manual of Operations. 1986. https://biolincc.nhlbi.nih.gov/static/studies/solvd/Manual_of_Operations_June_1986.pdf (25 January 2017).
dc.identifier.citedreferenceYusuf S, Pitt B, Davis CE, Hood WB, Cohn JN; SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293 – 302.
dc.identifier.citedreferencePonikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González‐Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18:891–975.
dc.identifier.citedreferenceYancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147 – 239.
dc.identifier.citedreferenceKomajda M, Anker SD, Cowie MR, Filippatos GS, Mengelle B, Ponikowski P, Tavazzi L; QUALIFY Investigators. Physicians’ adherence to guideline‐recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail 2016; 18: 514 – 522.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhf937.pdf
Size:
512.8KB
Format:
PDF
View/Open
Name:
ejhf937_am.pdf
Size:
400.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.